

Medicare Advantage Medical Utilization Review Policy

Policy:	Inflammatory Conditions – Infliximab Products Utilization Management Medical Policy • Avsola™ (infliximab-axxq intravenous infusion – Amgen) • Inflectra® (infliximab-dyyb intravenous infusion – Hospira/Pfizer) • Infliximab intravenous infusion – Janssen/Johnson & Johnson • Remicade® (infliximab intravenous infusion – Janssen/Johnson & Johnson) • Renflexis® (infliximab-abda intravenous infusion – Samsung Bioepis/Organon)
Date:	08/31/2026
Applicable Lines of Business:	Medicare Advantage - Medical
Applicable States:	Palmetto, JJ: Alabama, Georgia, Tennessee Palmetto, JM: North Carolina, South Carolina, Virginia, West Virginia
Applicable NCDs, LCDs, and/or LCAs	L35677, A56432

SUMMARY OF EVIDENCE

Infliximab products are tumor necrosis factor inhibitors (TNFis) approved for the following indications:^{1-3,26}

- **Ankylosing spondylitis**, for reducing signs and symptoms of active disease.
- **Crohn's disease**, for the following uses:
 - Reducing the signs and symptoms and inducing and maintaining clinical remission in patients ≥ 6 years of age with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy; AND
 - Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adults with fistulizing Crohn's disease.
- **Plaque psoriasis**, for treatment of adults with chronic severe (i.e., extensive and/or disabling) disease who are candidates for systemic therapy and when other systemic therapies are less appropriate.
- **Psoriatic arthritis**, for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function.
- **Rheumatoid arthritis**, in combination with methotrexate for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease.
- **Ulcerative colitis**, for the following uses:
 - Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adults with moderately to severely active disease who have had an inadequate response to conventional therapy; AND
 - Reducing signs and symptoms and inducing and maintaining clinical remission in patients ≥ 6 years of age with moderately to severely active disease who have had an inadequate response to conventional therapy.

Avsola, Inflectra, and Renflexis were approved as biosimilar to Remicade, indicating no clinically meaningful differences in safety and effectiveness and the same mechanism of action, route of administration, dosage form, and strength as Remicade.^{2-3,26} However, minor differences in clinically inactive components are allowed. At this time, only biosimilarity has been demonstrated (not interchangeability).

Guidelines

08/31/2026

© Express Scripts Strategic Development, Inc., 2026. All Rights Reserved.

This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.

TNFis feature prominently in guidelines for treatment of many inflammatory conditions.

- **Ankylosing Spondylitis and Non-Radiographic Spondyloarthritis:** Guidelines for ankylosing spondylitis and non-radiographic axial spondyloarthritis are published by the American College of Rheumatology (ACR)/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (2019).⁴ Following primary nonresponse to a TNFi, an interleukin (IL)-17 blocker is recommended; however, if the patient is a secondary nonresponder, a second TNFi is recommended over switching out of the class. In patients with a contraindication to a TNFi, use of an IL-17 blocker is recommended over traditional oral agents such as methotrexate or sulfasalazine.
- **Crohn's Disease:** The American College of Gastroenterology (ACG) [2025] and the American Gastroenterological Association (AGA) [2025] have guidelines for the management of Crohn's disease in adults.^{5,6} Both guidelines recommend upfront use of advanced therapies, rather than step-up therapy after failure of corticosteroids and/or immunomodulators. Advanced therapies recommended include TNF inhibitors, Entyvio® (vedolizumab intravenous infusion, subcutaneous injection), interleukin (IL)-23 inhibitors, IL-12/23 inhibitors, and Rinvoq® (upadacitinib extended-release tablets).
- **Plaque Psoriasis:** Guidelines from the American Academy of Dermatologists (AAD) and National Psoriasis Foundation (NPF) [2019] recommend infliximab as a monotherapy treatment option for adults with moderate to severe disease.⁷ Additionally, the AAD/NPF acknowledge conventional systemic agents (e.g., methotrexate, cyclosporin, acitretin) as alternative treatment options for the management of moderate to severe psoriasis.²⁴ In clinical trials cited within the guidelines, the efficacy of these conventional agents were generally assessed at 12 weeks and beyond. Guidelines from the European Dermatology Forum (2025) recommend biologics as second-line therapy for most patients with moderate to severe psoriasis requiring systemic treatment when there is inadequate response, contraindication, or intolerance to conventional systemic agents.²⁵
- **Psoriatic Arthritis:** Guidelines from ACR (2019) recommend TNFis over other biologics for use in treatment-naïve patients with psoriatic arthritis, and in those who were previously treated with an oral therapy.⁸
- **Rheumatoid Arthritis:** Guidelines from ACR (2021) recommend addition of a biologic or a targeted synthetic disease modifying anti-rheumatic drug (DMARD) for a patient taking the maximum tolerated dose of methotrexate who is not at target.⁹
- **Ulcerative Colitis:** The AGA (2024) and the ACG (2025) have clinical practice guidelines on the management of moderate to severe ulcerative colitis.^{10,11} In moderate to severe disease, systemic corticosteroids or advanced therapies may be utilized for induction of remission. Advanced therapies recommended include TNF inhibitors, Entyvio, IL-23 inhibitors, IL-12/23 inhibitors, sphingosine-1-phosphate (S1P) receptor modulators, and Janus kinase (JAK) inhibitors. If steroids are utilized for induction, efforts should be made to introduce steroid-sparing agents for maintenance therapy. Of note, guidelines state corticosteroids may be avoided entirely when other effective induction strategies are planned.¹¹ Both guidelines also recommend that any drug that effectively treats induction should be continued for maintenance.^{10,11}
- **Behcet's Disease:** The European League Against Rheumatism (EULAR) recommendations (2018) include TNFis for initial or recurrent sight-threatening uveitis.¹³ For patients refractory to first-line treatments (e.g., corticosteroids), TNFis are among the treatment options for mucocutaneous manifestations, venous thrombosis, severe or refractory gastrointestinal disease, and recurrent/chronic joint involvement. Recommendations for the use of TNFis in ocular inflammatory disorders from the American Academy of Ophthalmology (AAO) [2014] note that TNFis may be used first-line in patients with ophthalmic manifestations of Behcet's disease and for acute exacerbations of pre-existing Behcet's disease.¹⁴
- **Graft-Versus-Host Disease (GVHD):** Guidelines for hematopoietic cell transplantation from the National Comprehensive Cancer network (NCCN) [version 3.2025 – September 24, 2025] list infliximab among the agents used for steroid-refractory acute GVHD.¹⁵ For patients with steroid-

refractory acute GVHD, Jakafi® (ruxolitinib tablets) is the only category 1 recommended agent. Other alternative agents recommended by NCCN for acute GVHD (category 2A) include the following: alemtuzumab IV infusion, alpha-1 antitrypsin, anti-thymocyte globulin, Simulect® (basiliximab), calcineurin inhibitors (e.g., tacrolimus, cyclosporine), Enbrel® (etanercept), extracorporeal photopheresis, infliximab, mammalian target of rapamycin inhibitors (e.g., sirolimus), mycophenolate mofetil, Nipent™ (pentostatin), tocilizumab, urinary-derived human chorionic gonadotropin/epidermal growth factor, and Entyvio® (vedolizumab)..¹⁵

- **Hidradenitis Suppurativa:** Guidelines from the US and Canadian Hidradenitis Suppurativa Foundations make recommendations for topical, intralesional, and systemic medical management of disease.¹⁶ For acute lesions of all stages, antiseptic washes, short-term oral steroids, and interlesional steroids are among the recommendations. Systemic antibiotics have been a mainstay of treatment. Infliximab is a recommended therapy for moderate to severe disease.
- **Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitors:** NCCN has guidelines (version 1.2026 – October 23, 2025) for Management of Checkpoint Inhibitor-Related Toxicities.¹⁷ Infliximab is recommended among the alternatives to manage steroid-refractory toxicities related to immune checkpoint inhibitors including inflammatory arthritis, uveitis, myocarditis, stage 3 acute kidney injury/elevated serum creatinine, pneumonitis, esophagitis, gastritis, duodenitis, and diarrhea/colitis. Additionally, the guidelines also note that infliximab has not been tested and is not recommended for immune-related hepatotoxicity due to concerns of liver toxicity.
- **Indeterminate Colitis:** Infliximab has been effective in some patients with refractory indeterminate colitis (retrospective reviews).^{18,19} When patients who are refractory to standard therapy can be definitively classified as having ulcerative colitis, colectomy is considered an effective long-term surgical treatment. Patient's with Crohn's disease; however, have a high risk of complications after ileal pouch-anal anastomosis and are treated more aggressively with medical interventions since surgical options cannot offer the same likelihood of success as in ulcerative colitis.
- **Juvenile Idiopathic Arthritis (JIA):** There are guidelines from ACR and the Arthritis Foundation for the treatment of JIA (2021) which address oligoarthritis and temporomandibular joint (TMJ) arthritis.²⁰ For oligoarthritis, a biologic is recommended following a trial of a conventional synthetic DMARD. In patients with TMJ arthritis, scheduled nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular glucocorticoids are recommended first-line. A biologic is a therapeutic option if there is an inadequate response or intolerance. Additionally, rapid escalation to a biologic ± conventional synthetic DMARD (methotrexate preferred) is often appropriate given the impact and destructive nature of TMJ arthritis. In these guidelines, there is not a preferred biologic that should be initiated for JIA. The ACR/Arthritis Foundation Guideline for the treatment of JIA (2019) provides updated recommendations for juvenile non-systemic polyarthritis, sacroiliitis, and enthesitis.²¹ Infliximab is among the TNFis recommended as subsequent therapy following treatment with a conventional synthetic DMARD such as methotrexate. TNF antagonists such as infliximab may also be used as second- or third-line treatment for systemic JIA.²²
- **Ocular Inflammatory Disorders:** Recommendations for the use of TNFis in ocular inflammatory disorders from the AAO (2014) note that infliximab may be used as second-line corticosteroid-sparing therapy for chronic and severe scleritis.¹⁴ Infliximab may be used in patients with uveitis due to various causes (e.g., spondyloarthropathy-associated or human leukocyte antigen [HLA]-B27-associated uveitis, juvenile idiopathic arthritis-associated uveitis, and other posterior uveitides and panuveitis syndromes). Infliximab should be considered second-line in vision-threatening JIA-associated uveitis when methotrexate has failed or is not tolerated (strong recommendation) and vision-threatening chronic uveitis from seronegative spondyloarthropathy (strong recommendation). Infliximab may also be considered in other patients who have vision-threatening or corticosteroid-dependent disease who have failed first-line therapies. The recommendations

point out that studies evaluating infliximab in uveitis included patients with birdshot chorioretinitis (BSCR), a bilateral posterior uveitis generally treated with systemic immunomodulation; these patients showed a good response to infliximab.

- **Pyoderma Gangrenosum:** There are currently no formal US consensus guidelines specifically dedicated to the diagnosis and management of pyoderma gangrenosum published by major bodies like the AAD. However, clinical practice is informed by several comprehensive reviews and expert recommendations. Oral prednisone is the most common initial immunosuppressant medication.²³ Other systemic therapies include conventional systemic agents (e.g., cyclosporine, methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil) and TNFis (i.e., infliximab, etanercept, and adalimumab products). Of note, it is generally recognized that conventional systemic agents have a delayed onset of action; therefore, two months or longer is considered an adequate duration of therapy to elicit a clinical response.
- **Sarcoidosis:** The European Respiratory Society Task Force has guidelines for treatment of pulmonary, cutaneous, cardiac, and neurologic sarcoidosis.²⁴ Infliximab is a recommended therapy after continued disease or relapse while taking systemic corticosteroids and immunosuppressants (e.g., methotrexate, azathioprine, leflunomide, mycophenolate mofetil, hydroxychloroquine).

Dosing Information

The recommended dose of infliximab intravenous is weight-based and varies slightly by indication.¹⁻³ Dosing increase, interval shortening, or changing to another therapy is generally recommended for attenuation of response. Thus, published recommendations note that the dose and interval of infliximab may be adjusted, as needed, in patients who initially respond but then lose that response.² Additionally, data are emerging concerning tapering of infliximab dosage in patients with inflammatory conditions who are in remission or have low disease activity. When the dose of any RA therapy is tapered, it is recommended that there be a comprehensive plan to monitor disease activity and address possible flares.

ANALYSIS OF EVIDENCE

The information provided in the summary of evidence is supported by labeled indications, CMS-approved compendia, published clinical literature, clinical practice guidelines, and/or applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs). Refer to the Sources of Information section of this policy for additional information.

POLICY STATEMENT

Prior authorization is recommended for medical benefit coverage of infliximab products. Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), as well as in companion policy articles and other guidance applicable to the relevant service areas. These documents are cited in the Sources of Information section of this policy. In some cases, this guidance includes specific lists of HCPCS and ICD-10 codes to help inform the coverage determination process. The Articles that include specific lists for billing and coding purposes will be included in the Sources of Information section of this policy. However, to the extent that this policy cites such lists of HCPCS and ICD-10 codes, they should be used for reference purposes only. The presence of a specific HCPCS or ICD-10 code in a chart or companion article to an LCD is not by itself sufficient to approve coverage. Similarly, the absence of such a code does not necessarily mean that the applicable condition or diagnosis is excluded from coverage.

Note: Conditions for coverage outlined in this Medicare Advantage Medical Policy may be less restrictive than those found in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles. Examples of situations where this clinical policy may be less restrictive include, but are not limited to, coverage of additional indications supported by CMS-approved compendia and the exclusion from this policy of additional coverage criteria requirements outlined in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles.

Indications with a ^ below are referenced in both the corresponding Standard Medical Utilization Management Internal Policy AND applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs). Coverage criteria for these indications may be internally developed and/or referenced in applicable NCDs, LCDs, and/or LCAs. For these indications, internally developed coverage criteria is denoted throughout the policy in the following manner: 1) IC-L (internal criteria supported by the labeled indication), 2) IC-COMP (internal criteria supported by CMS-approved compendia), 3) IC-ISGP (internal criteria intended to interpret or supplement general provisions outlined in applicable NCDs, LCDs, and/or LCAs), or 4) IC-EC (internal criteria intended to expand coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs). For these indications, coverage criteria that is NOT denoted with one of the above indicators is referenced in applicable NCDs, LCDs, and/or LCAs. Additional information supporting the rationale for determination of internal coverage criteria can be found via the Sources of Information section.

Indications with a @ below are referenced in the corresponding Standard Medical Utilization Management Internal Policy, but are NOT directly referenced in applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs). Coverage criteria for these indications is internally developed. These indications and their respective coverage criteria represent expanded coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs.

Indications with a # below are supported and referenced in applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs), but are NOT directly referenced in the corresponding Standard Medical Utilization Management Internal Policy. Coverage criteria for these indications is referenced in applicable NCDs, LCDs, and/or LCAs.

RECOMMENDED AUTHORIZATION CRITERIA

FDA-Approved Indications

1. Ankylosing Spondylitis (AS). ^

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient is ≥ 18 years of age. ^{IC-L}

B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

i. Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

ii. Patient meets at least one of the following (a or b):

a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} OR

Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL),

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), Health Assessment Questionnaire for the Spondyloarthropathies (HAQ-S), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).

- b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy: Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 6 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

2. Crohn's Disease. ^

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient is greater than or equal to 6 years of age; ^{IC-L}
OR
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} OR
Note: Examples of objective measures include fecal markers (e.g., fecal lactoferrin, fecal calprotectin), serum markers (e.g., C-reactive protein), imaging studies (magnetic resonance enterography [MRE], computed tomography enterography [CTE]), endoscopic assessment, and/or reduced dose of corticosteroids.
 - b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or blood in stool. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

3. Plaque Psoriasis. ^

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 3 months if the patient meets the following criteria (i and ii):

- i. The patient is an adult greater than or equal to 18 years of age; AND
 - ii. The patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant or contraindicated. ^{IC-ISGP}
Note: Examples include methotrexate (MTX), cyclosporine, acitretin [Soriatane[®], generics], psoralen plus ultraviolet A light (PUVA) or ultraviolet B light (UVB). An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic (other than the requested medication), Otezla/Otezla XR (apremilast tablets/extended-release tablets), or Sotyktu (deucravacitinib tablets). A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for psoriasis. A patient who has already tried a biologic, Otezla/Otezla XR, or Sotyktu for psoriasis is not required to “step back” and try a traditional systemic agent for psoriasis.
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i. Patient has been established on therapy for at least 3 months; ^{IC-ISGP} AND
Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating an infliximab product) in at least one of the following: estimated body surface area affected, erythema, induration/thickness, and/or scale of areas affected by psoriasis; ^{IC-ISGP} AND
 - iii. Compared with baseline (prior to receiving an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, itching, and/or burning. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

4. Psoriatic Arthritis (PsA). [^]

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient is $\geq$ 18 years of age. ^{IC-L}
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} OR
Note: Examples of objective measures of disease activity include Disease Activity Index for Psoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PsA DAS), Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA), Psoriatic

Arthritis Impact of Disease (PsAID-12), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).

- b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

5. Rheumatoid Arthritis (RA). [^]

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets the following (i and ii):

- i. Patient is ≥ 18 years of age; ^{IC-L} AND
- ii. Patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months. ^{IC-ISGP}

Note: Examples include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient has already had a 3-month trial at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for rheumatoid arthritis. A patient who has already tried a biologic is not required to “step back” and try a conventional synthetic DMARD.

- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND
- ii. Patient meets at least one of the following (a or b):

- a. Patient experienced a beneficial clinical response when assessed by at least one objective measure; ^{IC-ISGP} OR

Note: Examples of objective measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate or C-reactive protein, Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).

- b. Patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 3 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

6. Ulcerative Colitis. ^

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient is greater than or equal to 6 years of age; ^{IC-L}
OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i.** Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii.** Patient meets at least one of the following (a or b):
 - a.** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP}
OR
Note: Examples of objective measures include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.
 - b.** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or rectal bleeding. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg per kg as an IV infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

Other Uses with Supportive Evidence

7. Behcet's Disease (Behcet's Syndrome). ^

Criteria. Approve for the duration noted if the patient meets the following criteria (A or B):

- A) Initial Therapy.** Approve for 3 months if the patient meets one of the following conditions (i or ii):
- i.** The patient has tried at least ONE conventional therapy; OR
Note: Examples include systemic corticosteroids (e.g., methylprednisolone), immunosuppressants (azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, Leukeran[®] [chlorambucil tablet], cyclophosphamide, interferon alfa). An exception to the requirement for a trial of one conventional therapy can be made if the patient has already had a trial of at least one tumor necrosis factor inhibitor (e.g., an adalimumab product [e.g., Humira], an etanercept product [e.g., Enbrel]). A patient who has already tried one biologic other than the requested drug for Behcet's disease is not required to "step back" and try a conventional therapy. A biosimilar of the requested biologic does not count.
 - ii.** The patient has ophthalmic manifestations of Behcet's disease.

- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i.** Patient has been established on therapy for at least 3 months; ^{IC-ISGP} AND
Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii.** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} AND
Note: Examples of objective measures are dependent upon organ involvement but may include best-corrected visual acuity (if ophthalmic manifestations); serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate); or ulcer depth, number, and/or lesion size.
 - iii.** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or improved visual acuity (if ophthalmic manifestations). ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 6 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

8. Graft-Versus-Host Disease (GVHD). @

Criteria. Approve for the duration noted if the patient meets the following criteria (A or B):

- A) Initial Therapy.** Approve for 1 month if the patient meets the following (I, ii and iii):
- i.** Patient is ≥ 6 years of age; AND
 - ii.** Patient has acute graft-versus-host disease; AND
 - iii.** Patient has tried at least one systemic medication for graft-versus-host disease (GVHD).
Note: Examples of systemic medications include corticosteroids (e.g., methylprednisolone), antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate mofetil, Jakafi (ruxolitinib), Simulect (basiliximab), an etanercept product, sirolimus, Nipent (pentostatin), a tocilizumab product, and Entyvio (vedolizumab).
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 3 months if the patient meets BOTH of the following (i and ii):
- i.** Patient has been established on an infliximab product for at least 1 month; AND
Note: A patient who has received < 1 month of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii.** Patient meets at least one of the following (a or b):
 - a.** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: An example of objective measures is normalization of liver function tests, red blood cell count, or platelet count, or resolution of fever or rash.
 - b.** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as improvement in skin, oral mucosal, ocular, or gastrointestinal symptoms (e.g., nausea, vomiting, anorexia).

Dosing. Approve the following regimens (A and B):

- A) The dose is up to 10 mg per kg given intravenously; AND
- B) Doses are administered no more frequently than once weekly.

9. Hidradenitis Suppurativa. ^

Criteria. Approve for the duration noted if the patient meets the following criteria (A or B):

- A) Initial Therapy. Approve for 3 months if the patient has tried one other therapy. ^{IC-ISGP}
Note: Examples of other therapy include intralesional or oral corticosteroids (e.g., triamcinolone, prednisone), systemic antibiotics (e.g., clindamycin, dicloxacillin, erythromycin), and isotretinoin)
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
 - i. Patient has been established on therapy for at least 3 months; ^{IC-ISGP} AND
Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} AND
Note: Examples of objective measures include Hurley staging, Sartorius score, Physician Global Assessment, and Hidradenitis Suppurativa Severity Index.
 - iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or drainage of lesions, nodules, or cysts. ^{IC-ISGP}

Dosing. Approve the following regimens (A and B):

- A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.⁴⁷
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

10. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy. @

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, iii and iv):
Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous [IV] infusion), Opdivo (nivolumab IV infusion), Yervoy (ipilimumab IV infusion), Tecentriq (atezolizumab IV infusion), Bavencio (avelumab IV infusion), or Imfinzi (durvalumab IV infusion).
 - i. Patient is ≥ 18 years of age; AND
 - ii. According to the prescriber, patient developed an immunotherapy-related toxicity other than hepatitis; AND
 - iii. The patient developed this immunotherapy-related toxicity while receiving a checkpoint inhibitor; AND
 - iv. The patient has tried a systemic corticosteroid.
Note: Examples include methyprednisone and prednisone.
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: Examples of objective measures are dependent upon organ involvement but may include clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), fecal markers (e.g., fecal calprotectin), and/or reduced dosage of corticosteroids.
 - b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness or swelling (if joint symptoms), stool frequency and/or rectal bleeding (if gastrointestinal symptoms), and/or improved function or activities of daily living.

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 10 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 4 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

11. Indeterminate Colitis. @

Note: Indeterminate colitis is defined as colitis that cannot be classified with certainty as either ulcerative colitis or Crohn's disease.

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets both of the following (i and ii):
 - i. The patient is greater than or equal to 6 years of age; AND
 - ii. The patient has tried at least one conventional therapy.
Note: Examples include a systemic corticosteroid (for example, prednisone, methylprednisolone), mesalamine, azathioprine, 6-mercaptopurine.
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: Examples of objective measures include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.
 - b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or rectal bleeding.

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

12. Juvenile Idiopathic Arthritis (JIA). @

Note: This includes JIA regardless of type of onset, including a patient with juvenile spondyloarthropathy/active sacroiliac arthritis. JIA is also referred to as Juvenile Rheumatoid Arthritis.

Criteria. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets the following (i and ii):
 - i. Patient is ≥ 6 years of age; AND
 - ii. Patient meets one of the following criteria (a or b):
 - a. Patient has tried one other systemic medication for this condition; OR
Note: Examples of other medications for JIA include methotrexate (MTX), sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID) [e.g., ibuprofen, naproxen]. A previous trial of one biologic other than the requested medication also counts as a trial of one medication. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for JIA.
 - b. The patient has aggressive disease, as determined by the prescriber.
- B) Patient is Currently Receiving an Infliximab Product Approve for 1 year if the patient meets BOTH of the following (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: Examples of objective measures include Physician Global Assessment (MD global), Parent/Patient Global Assessment of Overall Well-Being (PGA), Parent/Patient Global Assessment of Disease Activity (PDA), Juvenile Arthritis Disease Activity Score (JDAS), Clinical Juvenile Arthritis Disease Activity Score (cJDAS), Juvenile Spondyloarthritis Disease Activity Index (JSpADA), serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.
 - b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as improvement in limitation of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, or improved function or activities of daily living.

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 6 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

13. Pyoderma Gangrenosum. @

Criteria. Approve for the duration noted if the patient meets the following criteria (A or B):

A) Initial Therapy. Approve for 4 months if the patient meets the following (i and ii):

i. Patient is ≥ 18 years of age; AND

ii. Patient meets one of the following conditions (a or b):

a. The patient has tried one systemic corticosteroid; OR

Note: An example is prednisone.

b. The patient has tried one other immunosuppressant for at least 2 months or was intolerant to one of these medications.

Note: Examples include mycophenolate mofetil and cyclosporine

C) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):

i. Patient has been established on therapy for at least 4 months; AND

Note: A patient who has received < 4 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating an infliximab product) in at least one of the following: size, depth, and/or number of lesions; AND

iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain and/or tenderness of affected lesions.

Dosing. Approve the following regimens (A or B):

A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.⁸⁶

B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

14. Sarcoidosis. ^

Criteria. Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

A) Initial Therapy. Approve for 3 months if the patient meets both of the following conditions (i and ii):

i. The patient has tried at least one corticosteroid. ^{IC-ISGP}

Note: An example is prednisone; AND

ii. The patient has tried at least one immunosuppressive medication, unless intolerant or contraindicated. ^{IC-ISGP}

Note: Examples include methotrexate, azathioprine, leflunomide, mycophenolate mofetil, hydroxychloroquine, cyclophosphamide, or chloroquine.

B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):

i. Patient has been established on therapy for at least 3 months; ^{IC-ISGP} AND

Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

ii. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} AND

Note: Examples of objective measures are dependent upon organ involvement but may include lung function (e.g., predicted forced vital capacity and/or 6-minute walk distance); serum markers (e.g., C-reactive protein, liver enzymes, N-terminal pro-brain natriuretic peptide [NT-proBNP]); improvement in rash or skin manifestations, neurologic symptoms, or rhythm control; or imaging (e.g., if indicated, chest radiograph, magnetic resonance imaging [MRI], or echocardiography).

- iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased cough, fatigue, pain, palpitations, neurologic symptoms, and/or shortness of breath.^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

- C) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 6 weeks thereafter.¹
- D) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

15. Scleritis or Sterile Corneal Ulceration. @

Criteria. Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets the following (i and ii):

- i. Patient is ≥ 18 years of age; AND
- ii. Patient has tried one other therapy for this condition.

Note: Examples include oral non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin; oral, topical (ophthalmic) or IV corticosteroids (such as prednisone, prednisolone, methylprednisolone); methotrexate (MTX); cyclosporine; or other immunosuppressants.

- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least one of the following (a or b):
 - a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: Examples of objective measures are serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
 - b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased eye pain, redness, light sensitivity, tearing, and/or improvement in visual acuity.

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 10 mg per kg as an IV infusion administered at baseline and followed by up to three additional similar doses (for example, up to three additional doses given 2, 6, and 8 weeks after the initial infusion).
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

16. Spondyloarthritis (SpA), Other Subtypes. ^ (Note: Examples of other subtypes include undifferentiated arthritis, non-radiographic axial SpA, Reactive Arthritis [Reiter's disease], including Reactive Arthritis associated with Inflammatory Bowel Disease.²⁸ For AS or PsA, refer to the respective criteria under FDA-approved indications)

Criteria. Approve for the duration noted if ONE of the following conditions are met (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets one of the following conditions (i or ii):

- i. The patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) has been tried; ^{IC-ISGP} OR

Note: Examples include methotrexate [MTX], leflunomide, sulfasalazine.

- ii. The patient has axial spondyloarthritis AND has objective signs of inflammation, defined as at least one of the following [1 or 2]: ^{IC-EC}

1. C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory; ^{IC-EC} OR

2. Sacroiliitis reported on magnetic resonance imaging (MRI). ^{IC-EC}

B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; ^{IC-ISGP} AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least one of the following (a or b):

- a. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); ^{IC-ISGP} OR

Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS) and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).

- b. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living. ^{IC-ISGP}

Dosing. Approve the following regimens (A or B):

A) Initial Therapy. Approve up to 5 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 6 weeks thereafter.

B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

17. Uveitis. @

Note: This includes other posterior uveitides and panuveitis syndromes.

Criteria. Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets the following (i and ii):

- i. Patient is ≥ 6 years of age; AND

- ii. Patient has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids, or immunosuppressives.

Note: Examples of corticosteroids include prednisolone, triamcinolone, betamethasone, methylprednisolone, prednisone. Examples of immunosuppressives include methotrexate (MTX), mycophenolate mofetil, and cyclosporine. An exception to the requirement for a trial of one of these therapies can be made if the patient has already had a trial of an etanercept product or an adalimumab product for uveitis. A patient who has already tried one biologic other than the requested medication also counts. A biosimilar of the requested biologic does not count.

B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
- ii. Patient meets at least one of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
Note: Examples of objective measures include best-corrected visual acuity, assessment of chorioretinal and/or inflammatory retinal vascular lesions, or anterior chamber cell grade or vitreous haze grade.
 - b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased eye pain, redness, light sensitivity, and/or blurred vision; or improvement in visual acuity.

Dosing. Approve the following regimens (A or B):

- A) Initial Therapy. Approve up to 10 mg per kg as an IV infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 4 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

Conditions Not Recommended for Approval

Coverage of infliximab products is not recommended in the following situations:

1. **Concurrent Use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug.** This medication should not be administered in combination with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.
Note: This does NOT exclude the use of conventional synthetic disease-modifying antirheumatic drug (e.g., methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) in combination with this medication.
1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

SOURCES OF INFORMATION

1. Infliximab intravenous infusion [prescribing information]. Horsham, PA: Janssen; October 2021.
2. Inflectra® intravenous infusion [prescribing information]. Yeonsu-gu, Incheon, Republic of Korea: Celltrion/Pfizer; September 2025.
3. Renflexis® intravenous infusion [prescribing information]. Jersey City, NJ: Samsung Bioepis/Organon; October 2025.

4. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2019;(10):1599-1613.
5. Lichtenstein G, Loftus E, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2025 June;120(6):1225-1264.
6. Scott FI, Ananthakrishnan AN, Click B, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. *Gastroenterology*. 2025 Dec;169(7):1397-1448.
7. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
8. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29.
9. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123.
10. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*. 2024 Dec;167(7):1307-1343.
11. Rubin D, Ananthakrishnan A, Siegel C. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J of Gastroenterol*. 2025 June;120(6):1187-1224.
12. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*. 2018;77(6):808-818.
13. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121(3):785-796.
14. The NCCN Hematopoietic Cell Transplantation (HCT) Clinical Practice Guidelines in Oncology (version 3.2025 – September 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 10, 2025.
15. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019;81(1):91-101.
16. The NCCN Management of Immune Checkpoint Inhibitor-Related Toxicities Clinical Practice Guidelines in Oncology (version 1.2026 – October 23, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed December 10, 2025.
17. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. *Aliment Pharmacol Ther*. 2003;18:741-747.
18. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *Aliment Pharmacol Ther*. 2003;18:175-181.
19. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol*. 2022 Apr;74(4):553-569.
20. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol*. 2019;71(6):846-863.
21. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013;65(10):2499-2512.
22. Łyko M, Ryguła A, Kowalski M, Karska J, Jankowska-Konsur A. The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives. *Int J Mol Sci*. 2024 Feb 19;25(4):2440.
23. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
24. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.
25. Nast A, Spuls PI, Dressler C, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris. Updated February 2025. Available at: <https://www.guidelines.edf.one/guidelines/psoriasis-guideline>. Accessed on: October 20, 2025.
26. Avsola® intravenous infusion [prescribing information]. Thousand Oaks, CA: Amgen; August 2025.
27. Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD): Infliximab (L35677) [Original effective date: 10/01/2015; Revision effective date: 08/08/2024]. Accessed on August 31, 2026.
28. Centers for Medicare and Medicaid Services. Local Coverage Article (LCA): Billing and Coding: Infliximab (A56432) [Original effective date: 4/11/2019; Revision effective date: 1/1/2026]. Accessed on August 31, 2026.

HISTORY

Type of Revision	Summary of Changes	Date
Policy created	New Medicare Advantage Medical Policy	1/1/2019
Policy revision	Dosing: Throughout the policy, for select indications dosing was updated to clarify the dose which may be approved up to the maximum dose and shortest treatment interval listed in the dosing criteria for each indication. All wording that referred to patients who had an inadequate response was removed from the dosing section (not needed – already included in the criteria section of the policy). Behcet's Disease, GVHD, Hidradentitis Suppurativa, Pyoderma Gangrenosum, Sarcoidosis: For patients currently receiving therapy, the requirement that patients be on an infliximab product for ≥ 90 days was removed.	9/11/2019
Policy revision	*Added the following indications: Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy, Indeterminate Colitis, Scleritis or Sterile Corneal Ulceration, Still's Disease, Spondyloarthritis (SpA), Other Subtypes (in addition to Reiter's disease, which was already included in the policy) * RA - added requirement for trial of one conventional therapy * CD - removed requirement for disease severity, added criteria for enterocutaneous (perianal or abdominal) or rectovaginal fistulas, and for ileocolonic resection * PP - removed disease severity requirement * UC - added exception to conventional therapy trial requirement if patient has pouchitis AND has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine) enema. * Behcet's disease - added requirement that patient have clinical manifestations of Behcet's disease, added exception to requirement of trial of conventional therapy if patient has ophthalmic manifestations.	1/28/2020
Policy revision	*Non-clinical update to policy to add the statement "This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), as well as in companion policy articles and other guidance applicable to the relevant service areas. These documents are cited in the References section of this policy. In some cases, this guidance includes specific lists of HCPCS and ICD-10 codes to help inform the coverage determination process. The Articles that include specific lists for billing and coding purposes will be included in the Reference section of this policy. However, to the extent that this policy cites such lists of HCPCS and ICD-10 codes, they should be used for reference purposes only. The presence of a specific HCPCS or ICD-10 code in a chart or companion article to an LCD is not by itself sufficient to approve coverage. Similarly, the absence of such a code does <u>not</u> necessarily mean that the applicable condition or diagnosis is excluded from coverage." *Added Palmetto JM (NC, SC, VA, and WV) to Applicable States section	1/30/2020
Policy revision	*Throughout policy, for continuation criteria where required that response be demonstrated by a reduction in signs/symptoms, criteria was changed to require the response be as determined by the prescriber *Crohn's disease, Plaque psoriasis, Ulcerative colitis - Added note that trial of biologic counts as trial of one other agent *Crohn's disease and ulcerative colitis - - added age requirement of 6 years or older *Rheumatoid arthritis - Removed requirement that infliximab be taken in combination with MTX, unless intolerant or contraindicated *Behcet's disease - added note "An exception to the requirement for a trial of one conventional therapy can be made if the patient has already had a trial of at least one tumor necrosis factor inhibitor (e.g., an adalimumab product [e.g., Humira], an etanercept product [e.g., Enbrel]). These patients who have already tried a biologic for Behcet's disease are not	4/7/2020

08/31/2026

© Express Scripts Strategic Development, Inc., 2026. All Rights Reserved.

This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.

	required to “step back” and try a conventional therapy)” and removed criteria requirement that patient have clinical manifestations of Behcet’s *Hidradenitis suppurativa - modified criteria requirement from required trial of systemic antibiotics or surgical treatments to “one other therapy” (less restrictive) *Sarcoidosis - removed requirement that trial of steroids and immunosuppressants be 3 months or more and that steroids be given at a dose of 10 mg or more per day *Conditions not recommended for coverage - removed patients with stage III or IV CHF, and those with untreated active or latent TB * Added the following note to the policy statement – “Note: Conditions for coverage outlined in this Medicare Advantage Medical Policy may be less restrictive than those found in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles. Examples of situations where this clinical policy may be less restrictive include, but are not limited to, coverage of additional indications supported by CMS-approved compendia and the exclusion from this policy of additional coverage criteria requirements outlined in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles.”	
Policy revision	Avsola (infliximab-axxq for injection, for intravenous use) [biosimilar to Remicade] was added to the policy. Criteria are the same as for the other infliximab products. Throughout the policy, examples of infliximab products were replaced with a general reference to infliximab products.	06/18/2020
Policy revision	Crohn’s Disease: Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section). For the criterion applying to previous therapy, wording was changed to specify this must have been a conventional systemic therapy (criteria previously required a trial of one other agent, with conventional systemic agents listed among the examples). Plaque Psoriasis: Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section). Rheumatoid Arthritis: Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section). Ulcerative Colitis: Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section). Graft Versus Host Disease (GVHD): To align with updated guidelines and other policies, criteria were changed to require at least one conventional systemic treatment prior to an infliximab product. Previously, criteria required that the patient had tried at least one other immunosuppressant or be concurrently receiving an immunosuppressant in combination with an infliximab product. Juvenile Idiopathic Arthritis: Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section).	09/30/2020
Policy revision	Juvenile Idiopathic Arthritis: The approval condition was reworded to as listed. Previously the indication also included Juvenile Rheumatoid Arthritis (regardless of type of onset), which was moved into a Note. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy: The requirement that the patient has an immunotherapy-related toxicity was reworded to generally refer to an immunotherapy-related toxicity other than hepatitis. Specific toxicities related to the gastrointestinal system, inflammatory arthritis, and ocular toxicity were moved from the criteria into a note representing examples of various immunotherapy-related toxicities. Uveitis: The approval condition was reworded to as listed. Previously, the indication included other posterior uveitides and panuveitis syndromes, which was moved into a note.	10/22/2021
Policy revision	Infliximab intravenous infusion (authorized generic to Remicade) was added to the policy. Criteria are the same as the other infliximab products addressed in the policy.	12/29/2021

Policy revision	Ankylosing Spondylitis: Initial approval duration was changed to 6 months (previously was 3 months). For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Crohn's Disease: Initial approval duration was changed to 6 months (previously was 3 months). Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. A note was added to clarify that a trial of mesalamine does not count as a systemic agent for Crohn's disease. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Plaque Psoriasis: Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 90 days. Requirements were added that for a patient who is currently receiving an infliximab product, the patient must have at least one objective <u>and</u> at least one subjective response to therapy. Previously, response was more general and according to the prescriber. Psoriatic Arthritis: Initial approval duration was changed to 6 months (previously was 3 months). For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Rheumatoid Arthritis: Initial approval duration was changed to 6 months (previously was 3 months). Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Ulcerative Colitis: Initial approval duration was changed to 6 months (previously was 3 months). Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Behcet's Disease: Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 90 days. Requirements were added that for a patient who is currently receiving an infliximab product, the patient must have at least one objective <u>and</u> at least one subjective response to therapy. Previously, response was more general and according to the prescriber.	11/28/2022
-----------------	---	------------

08/31/2026

© Express Scripts Strategic Development, Inc., 2026. All Rights Reserved.

This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.

	Graft-Versus-Host Disease: For a patient currently receiving, it was clarified that this applies to a patient who is receiving an infliximab product for ≥ 1 month. Requirements were added for a patient who is currently receiving, that there has been at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Hidradenitis Suppurativa: For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an adalimumab product for ≥ 90 days. Requirements were added that for a patient who is currently receiving an infliximab product, the patient must have at least one objective <u>and</u> at least one subjective response to therapy. Previously, response was more general and according to the prescriber. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy: Initial approval duration was changed to 6 months (previously was 3 months). For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Indeterminate Colitis: The definition of indeterminate colitis (colitis that cannot be classified with certainty as either ulcerative colitis or Crohn's disease) was moved to a note; previously this was included in the indication. Initial approval duration was changed to 6 months (previously was 3 months). For initial approval, requirement to try both mesalamine and either azathioprine or 6-mercaptopurine was changed to trial of at least one conventional therapy For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Juvenile Idiopathic Arthritis: Initial approval duration was changed to 6 months (previously was 3 months). Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. For continuation, approvals were changed to be 1 year in duration. Previously, response was more general and according to the prescriber, and approvals were for 3 years. Pyoderma Gangrenosum: For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 4 months. Requirements were added that for a patient who is currently receiving an infliximab product, the patient must have at least one objective <u>and</u> at least one subjective response to therapy. Previously, response was more general and according to the prescriber. Sarcoidosis: To align with guidelines, the note that includes examples of immunosuppressive medications was updated to add leflunomide, mycophenolate mofetil, and hydroxychloroquine; cyclosporine, chlorambucil, and thalidomide were removed from the examples. Cardiologist and neurologist were added to the list of specialists who must prescribe or be consulted for this indication. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 90 days. Requirements were added that for a patient who is currently receiving an infliximab product, the patient must have at least one objective <u>and</u> at least one subjective response to therapy. Previously, response was more general and according to the prescriber.	
--	---	--

	Scleritis or Sterile Corneal Ulceration: Initial approval duration was changed to 6 months (previously was 3 months). For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Spondyloarthritis, Other Subtypes: Initial approval duration was changed to 6 months (previously was 3 months). For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Still's Disease: Initial approval duration was changed to 6 months (previously was 3 months). Note was updated to state that a previous trial of one biologic other than the requested drug counts towards a requirement for previous therapy. A biosimilar of the requested biologic does not count. For a patient currently receiving, it was clarified that this applies to a patient who is receiving an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber. Uveitis: Initial approval duration was changed to 6 months (previously was 3 months). Note was clarified to state that a previous trial of a biologic applies to at least one biologic other than the requested drug. A biosimilar of the requested biologic <u>does not count</u>. For a patient currently receiving an infliximab product, it was clarified that this applies to a patient who has received an infliximab product for ≥ 6 months. A requirement was added for a patient who is currently receiving an infliximab product to have at least one objective or subjective response to therapy. Previously, response was more general and according to the prescriber.	
Policy review	No criteria changes	12/13/2023
Policy revision	Plaque Psoriasis: For a patient currently taking an infliximab product, the timeframe for established on therapy was changed from 90 days to 3 months. Behcet's Disease: For a patient currently taking an infliximab product, the timeframe for established on therapy was changed from 90 days to 3 months. Hidradenitis Suppurativa: For a patient currently taking an infliximab product, the timeframe for established on therapy was changed from 90 days to 3 months. Sarcoidosis: For a patient currently taking an infliximab product, the timeframe for established on therapy was changed from 90 days to 3 months. Based on commercial policy revision	4/30/2024
Policy review	LCD/LCA update – no criteria changes.	09/09/2024
Policy revision	Ankylosing Spondylitis: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Psoriatic Arthritis: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Rheumatoid Arthritis: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Graft-vs-Host Disease: For initial approvals, a requirement that the patient is ≥ 6 years of age was added. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Juvenile Idiopathic Arthritis: For initial approvals, a requirement that the patient is ≥ 6 years of age was added. Pyoderma Gangrenosum: For initial approvals, a requirement that the patient is ≥ 18 years of age was added.	09/26/2024

	Scleritis or Sterile Corneal Ulceration: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Still's Disease: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Uveitis: For initial approvals, a requirement that the patient is ≥ 6 years of age was added. Conditions Not Recommended for Approval: Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug was changed to as listed (previously oral small molecule drug was listed as Disease-Modifying Antirheumatic Drug).	
Policy revision	Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy: Myalgia and myositis were removed from the examples of immunotherapy-related toxicities associated with checkpoint inhibitor therapy.	01/06/2025
Policy revision	No criteria changes. Formatting and notation updates.	07/30/2025
Policy revision	Graft-versus-Host Disease: For initial approvals, added the requirement that patient has acute graft-versus-host disease. Modified the requirement that patient has tried at least one conventional systemic treatment to at least one systemic medication. Jakafi (ruxolitinib), Simulect (basiliximab), an etanercept product, sirolimus, Nipent (pentostatin), a tocilizumab product, and Entyvio (vedolizumab) were added to the Note of examples of systemic medications. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy: “According to the prescriber” was added to the requirement that patient experienced an immunotherapy-related toxicity while receiving a checkpoint inhibitor and specific examples of immunotherapy-related toxicities were removed.	09/25/2025
Policy revision	Plaque Psoriasis: For initial therapy, in the Note, a 3-month trial or prior intolerance to Otezla/Otezla XR (apremilast tablets/extended-release tablets), or Sotyktu (deucravacitinib tablets) was added as an exception to the requirement for a trial of one traditional systemic agent for psoriasis. For initial therapy, the requirement “patient has a contraindication to methotrexate, as determined by the prescriber” was modified to “according to the prescriber, the patient has a contraindication to methotrexate”. In the Appendix, Otezla XR (apremilast extended-release tablets) was added under the Oral Therapies/Targeted Synthetic Oral Small Molecular Drugs.	11/11/2025
Policy review	No criteria changes, review of commercial policy.	01/16/2026
Policy revision	Crohn's Disease: For initial therapy, the following options of approval were removed: The patient has tried or is currently taking systemic corticosteroids, or corticosteroids are contraindicated; patient has tried one conventional systemic therapy for Crohn's disease along with the associated Note; patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Still's Disease: Removed this condition of approval from Other Uses with Supportive Evidence.	03/04/2026
Policy revision	Ulcerative Colitis: For initial therapy, removed the following options of approval: (1) the patient has tried one systemic therapy; (2) the patient has pouchitis and tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema.	08/31/2026

APPENDIX

	Mechanism of Action	Examples of Indications*
Biologics		
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA, RA
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Zymfentra® (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC

08/31/2026

© Express Scripts Strategic Development, Inc., 2026. All Rights Reserved.

This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.

Simponi[®], Simponi Aria[®] (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC IV formulation: AS, PJIA, PsA, RA
Tocilizumab Products (Actemra [®] IV, biosimilar; Actemra SC, biosimilar)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA IV formulation: PJIA, RA, SJIA
Kevzara[®] (sarilumab SC injection)	Inhibition of IL-6	RA
Orencia[®] (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan [®] , biosimilars)	CD20-directed cytolytic antibody	RA
Kineret[®] (anakinra SC injection)	Inhibition of IL-1	JIA [^] , RA
Omvoh[®] (mirikizumab IV infusion, SC injection)	Inhibition of IL-23	CD, UC
Ustekinumab Products (Stelara [®] IV, biosimilar; Stelara SC, biosimilar)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC
Siliq[®] (brodalumab SC injection)	Inhibition of IL-17	PsO
Cosentyx[®] (secukinumab SC injection; secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA
Taltz[®] (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Bimzelx[®] (bimekizumab-bkzx SC injection)	Inhibition of IL-17A/17F	PsO, AS, nr-axSpA, PsA
Ilumya[®] (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
Skyrizi[®] (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PSA, PsO, UC IV formulation: CD, UC
Tremfya[®] (guselkumab SC injection, guselkumab IV infusion)	Inhibition of IL-23	SC formulation: CD, PsA, PsO, UC IV formulation: CD, UC
Entyvio[®] (vedolizumab IV infusion, vedolizumab SC injection)	Integrin receptor antagonist	CD, UC
Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs		
Otezla[®] (apremilast tablets)	Inhibition of PDE4	PsO, PsA
Cibinqo[™] (abrocitinib tablets)	Inhibition of JAK pathways	AD
Olumiant[®] (baricitinib tablets)	Inhibition of JAK pathways	RA, AA
Litfulo[®] (ritlecitinib capsules)	Inhibition of JAK pathways	AA
Legselvi[®] (deuruxolitinib tablets)	Inhibition of JAK pathways	AA
Rinvoq[®] (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, CD, UC
Rinvoq[®] LQ (upadacitinib oral solution)	Inhibition of JAK pathways	PsA, PJIA
Sotyktu[®] (deucravacitinib tablets)	Inhibition of TYK2	PsO
Xeljanz[®] (tofacitinib tablets/oral solution)	Inhibition of JAK pathways	RA, PJIA, PsA, UC
Xeljanz[®] XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC
Zeposia[®] (ozanimod tablets)	Sphingosine 1 phosphate receptor modulator	UC
Velsipity[®] (etrasimod tablets)	Sphingosine 1 phosphate receptor modulator	UC

* Not an all-inclusive list of indications. Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; AA – Alopecia areata; TYK2 – Tyrosine kinase 2.